HUMA vs. CVAC, CALT, GPCR, AUPH, NAGE, AMPH, DYN, PAHC, BGM, and ABCL
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Aurinia Pharmaceuticals (AUPH), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), Phibro Animal Health (PAHC), BGM Group (BGM), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.
Humacyte vs. Its Competitors
Humacyte (NASDAQ:HUMA) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.
CureVac has a net margin of 35.44% compared to Humacyte's net margin of 0.00%. CureVac's return on equity of 30.89% beat Humacyte's return on equity.
In the previous week, Humacyte had 8 more articles in the media than CureVac. MarketBeat recorded 10 mentions for Humacyte and 2 mentions for CureVac. CureVac's average media sentiment score of 0.89 beat Humacyte's score of 0.48 indicating that CureVac is being referred to more favorably in the news media.
Humacyte has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.53, meaning that its share price is 153% more volatile than the S&P 500.
Humacyte presently has a consensus price target of $11.71, suggesting a potential upside of 371.40%. CureVac has a consensus price target of $6.83, suggesting a potential upside of 24.81%. Given Humacyte's stronger consensus rating and higher possible upside, analysts plainly believe Humacyte is more favorable than CureVac.
44.7% of Humacyte shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 5.1% of Humacyte shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
CureVac has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Summary
CureVac beats Humacyte on 9 of the 17 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Humacyte Competitors List
Related Companies and Tools
This page (NASDAQ:HUMA) was last updated on 7/10/2025 by MarketBeat.com Staff
